ZFP82 and breast cancer: We found that expression of ZNF545 was downregulated in 89.5% (17/19) of Luminal A (ER+/PR+/HER2−) subtypes, but increased in 69.2% (9/13) of triple negative (ER−/PR−/HER2−) and 87.5%(7/8) of Luminal B (ER+/PR+/HER2+) breast cancer tissues, compared with their adjacent non-tumor tissues (Fig. 1A, Table 2).